MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
about
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaMEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of AutophagyLong-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.Therapies on the horizon for childhood acute lymphoblastic leukemia.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.The landscape of new drugs in lymphomaNew drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Improvement of dexamethasone sensitivity by chelation of intracellular Ca2+ in pediatric acute lymphoblastic leukemia cells through the prosurvival kinase ERK1/2 deactivation.MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells.RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.Immunosuppressive efficacy of tetrandrine combined with methylprednisolone against mitogen-activated peripheral blood mononuclear cells of haemodialysis patients.Clonal evolution in leukemia.Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: The role of thymic stromal lymphopoietin.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.[Modulation of glucocorticoid sensitivity in acute lymphoblastic leukemia: Pyr3, a new therapeutic tool?]
P2860
Q28075504-A87CF054-07D9-4967-887D-4B4D55311716Q28075683-DF3EB8CA-ED45-4525-9988-14FD6C4E8E7BQ28552218-9F3A1A00-D832-4B30-9FFC-087D402E7A92Q36219840-14B64412-5216-4D79-A33C-BFDEDD0CBCC9Q36820322-2CD0A1E5-40AE-467C-9A26-8F512CF5A8A3Q37322952-5EFC88BB-FD44-4F49-81E8-E005E02F02BDQ38504437-B3E58D13-B50E-4912-8187-BE81C0F4A9DDQ38646974-E8BFD340-4DBE-4E00-9817-14E9980689C4Q39061630-4214A8AC-1532-4EA5-A1BB-4537F8835684Q39307476-0612B3A2-8C83-47A2-947B-BAF62D30D421Q39325783-1992D573-7019-4D42-B82A-10A386138808Q41906722-2589E1D4-8E60-4C29-BD74-6E1761E28C4DQ42314704-A3940CB0-9553-4B0D-92B2-FFF6B8A36E68Q46238878-B895B41C-4FB5-4932-BF71-8C6824674E61Q47875530-E56E7B3D-5B6A-4348-BDF6-78BA74CAE2D9Q47882529-92368C86-194B-4B50-8342-4AF1C759CC8DQ48279332-3A8850E6-55D0-42B1-AF38-1498C48BF86FQ49557852-FF3CF393-BB66-4A3E-B456-2FF9670CD65AQ50117976-DBB67000-29EC-4C28-827B-ADD35DC79FACQ51014811-EA01D997-9C9F-4B9B-AD26-296BD2BB1D7AQ51040026-E7576D60-061E-4829-A210-075B6B5578C3Q51839566-BF5755E3-C623-4C54-8038-22370C8895ABQ52374520-B5276856-8794-4258-953E-EC4142AE1A59Q53477239-43E5F793-D48D-414F-A9AD-5811A3B2EE59
P2860
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@ast
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@en
type
label
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@ast
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@en
prefLabel
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@ast
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@en
P2093
P2860
P1433
P1476
MAPK signaling cascades mediat ...... hanisms in pediatric leukemia.
@en
P2093
Angela J Waanders
Christopher C Porter
Christy M Gearheart
Courtney L Jones
Cristina Delgado-Martin
Danielle S Bitterman
David T Teachey
Elizabeth A Raetz
Eugene Park
P2860
P304
P356
10.1182/BLOOD-2015-04-639138
P407
P577
2015-08-31T00:00:00Z